Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.880
+0.340 (9.60%)
At close: Mar 9, 2026, 4:00 PM EDT
3.820
-0.060 (-1.55%)
After-hours: Mar 9, 2026, 7:59 PM EDT
Altimmune Revenue
In the year 2025, Altimmune had annual revenue of $41.00K with 105.00% growth. Altimmune had revenue of $26.00K in the quarter ending December 31, 2025, with 420.00% growth.
Revenue (ttm)
$41.00K
Revenue Growth
+105.00%
P/S Ratio
12,309.06
Revenue / Employee
$695
Employees
59
Market Cap
504.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.00K | 21.00K | 105.00% |
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | - |
| Dec 31, 2022 | -68.00K | -4.48M | - |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | 10.33M | -407.15K | -3.79% |
| Dec 31, 2017 | 10.74M | 7.50M | 231.82% |
| Dec 31, 2016 | 3.24M | -7.40M | -69.59% |
| Dec 31, 2015 | 10.64M | 450.46K | 4.42% |
| Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
| Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
| Dec 31, 2012 | 25.18M | 909.61K | 3.75% |
| Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
| Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
| Dec 31, 2009 | 27.55M | -5.36M | -16.29% |
| Dec 31, 2008 | 32.91M | 18.27M | 124.75% |
| Dec 31, 2007 | 14.64M | 12.98M | 780.39% |
| Dec 31, 2006 | 1.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Vanda Pharmaceuticals | 216.11M |
| Century Therapeutics | 113.34M |
| Zevra Therapeutics | 84.39M |
| ADC Therapeutics | 75.21M |
| Prothena Corporation | 9.68M |
ALT News
- 4 days ago - Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 days ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - GlobeNewsWire
- 4 weeks ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters
- 5 weeks ago - Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
- 5 weeks ago - Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire